CGEN insider transaction filings
COMPUGEN LTD — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-30. Screen CGEN transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 13 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 1,875 shares, $4,688 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: sale of 1,875 shares @ $2.50 ($4,688) by Levine Zurit, filed 2026-07-13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Levine Zurit — SVP, Business Development | 2 | — | 1 leg · 1,875 sh · $4,688 | 4 |
| Halevy Gilead — Director | 1 | — | — | 2 |
| Hukkelhoven Mathias — Director | 1 | — | — | 2 |
| Kredo Russo Sharon — SVP, Research & Discovery | 1 | — | — | 2 |
| Livnat Savitzky Kinneret — Director | 1 | — | — | 2 |
| Mahler Michelle — Chief Medical Officer | 1 | — | — | 2 |
| Perry Eran — Director | 1 | — | — | 2 |
| Silberman David — Chief Financial Officer | 1 | — | — | 2 |
| ZWEIFACH SANFORD S — Director | 1 | — | — | 2 |
| Cohen-Dayag Anat — Director | 1 | — | — | 1 |
+2 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — COMPUGEN LTD
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-30 | 4 | Levine Zurit — SVP, Business Development | Grant/award (A): 18,000 @ $0 · Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Cohen-Dayag Anat — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Ophir Eran — President and CEO, Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Silberman David — Chief Financial Officer | Grant/award (A): 19,500 @ $0 · Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Kredo Russo Sharon — SVP, Research & Discovery | Grant/award (A): 18,000 @ $0 · Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Ferre Pierre — Chief Operating Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Perry Eran — Director | Grant/award (A): 7,500 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Livnat Savitzky Kinneret — Director | Grant/award (A): 7,500 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | ZWEIFACH SANFORD S — Director | Grant/award (A): 7,500 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Halevy Gilead — Director | Grant/award (A): 7,500 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Hukkelhoven Mathias — Director | Grant/award (A): 7,500 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Mahler Michelle — Chief Medical Officer | Grant/award (A): 13,500 @ $0 · Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Levine Zurit — SVP, Business Development | Option exercise (M): 1,875 @ $0.83 · Sale (S): 1,875 @ $2.50 · Option exercise (M): 1,875 (derivative) @ $0 | EDGAR |
| 2026-04-27 | 4 | Levine Zurit — SVP, Business Development | Option exercise (M): 2,000 @ $1.15 · Sale (S): 2,000 @ $3.20 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-04-27 | 4 | Ophir Eran — President and CEO, Director | Option exercise (M): 5,000 @ $0.83 · Sale (S): 5,000 @ $3.20 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-04-15 | 4 | Ophir Eran — President and CEO, Director | Option exercise (M): 5,000 @ $0.83 · Sale (S): 5,000 @ $2.90 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-04-15 | 4 | Levine Zurit — SVP, Business Development | Option exercise (M): 2,000 @ $1.15 · Sale (S): 2,000 @ $2.80 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-04-15 | 4/A | Levine Zurit — SVP, Business Development | Option exercise (M): 1,125 @ $0.83 · Option exercise (M): 2,000 @ $1.15 · Sale (S): 3,125 @ $2.56 · Option exercise (M): 1,125 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | Levine Zurit — SVP, Business Development | Option exercise (M): 1,125 @ $0.83 · Option exercise (M): 2,000 @ $1.15 · Sale (S): 3,125 @ $2.56 · Option exercise (M): 1,125 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Levine Zurit — SVP, Business Development | Option exercise (M): 2,500 @ $0.83 · Sale (S): 2,500 @ $2.30 · Option exercise (M): 4,375 @ $0.83 · Option exercise (M): 1,000 @ $1.15 · Sale (S): 5,375 @ $2.42 · Option exercise (M): 2,500 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-03 | 4 | Levine Zurit — SVP, Business Development | Option exercise (M): 2,500 @ $0.83 · Option exercise (M): 1,000 @ $1.15 · Sale (S): 3,500 @ $2.20 · Option exercise (M): 2,500 (derivative) @ $0 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Ophir Eran — President and CEO, Director | Option exercise (M): 5,625 @ $0.83 · Sale (S): 5,625 @ $2.21 · Option exercise (M): 5,625 (derivative) @ $0 | EDGAR |
| 2026-03-30 | 4 | Levine Zurit — SVP, Business Development | Option exercise (M): 11,875 @ $0.83 · Sale (S): 11,875 @ $2.04 · Option exercise (M): 11,875 (derivative) @ $0 | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CGEN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →